Identification of polypharmacological anticancerous molecules against Aurora kinase family of proteins.
Deepali GuptaMukesh KumarMandeep SinghMohd SalmanUddipan DasPunit KaurPublished in: Journal of cellular biochemistry (2022)
The Human Aurora Kinase (AURK) protein family is the key player of cell cycle events including spindle assembly, kinetochore formation, chromosomal segregation, centrosome separation, microtubule dynamics, and cytokinesis. Their aberrant expression has been extensively linked with chromosomal instability in addition to derangement of multiple tumor suppressors and oncoprotein regulated pathways. Therefore, the AURK family of kinases is a promising target for the treatment of various types of cancer. Over the past few decades, several potential inhibitors of AURK proteins have been identified and have reached various phases of clinical trials. But very few molecules have currently crossed the safety criteria due to their various toxic side effects. In the present study, we have adopted a computational polypharmacological strategy and identified four novel molecules that can target all three AURKs. These molecules were further investigated for their binding stabilities at the ATP binding pocket using molecular dynamics based simulation studies. The molecules selected adopting a multipronged computational approach can be considered as potential AURKs inhibitors for cancer therapeutics.
Keyphrases
- cell cycle
- molecular dynamics
- clinical trial
- papillary thyroid
- binding protein
- squamous cell
- cell proliferation
- poor prognosis
- transcription factor
- protein kinase
- density functional theory
- tyrosine kinase
- squamous cell carcinoma
- gene expression
- dna methylation
- high resolution
- dna binding
- mass spectrometry
- induced pluripotent stem cells
- liquid chromatography
- climate change
- risk assessment
- protein protein
- open label
- childhood cancer
- bioinformatics analysis
- young adults
- phase iii
- high speed
- case control